In Brief: CibaVision Voltaren ophthalmic
CibaVision Voltaren ophthalmic: Diclofenac sodium .1% solution adds indication July 23 for photophobia in patients undergoing incisional refractive surgery. Voltaren ophthalmic was first approved for treatment of inflammation following cataract surgery. The SNDA (20-37/S-007) was submitted on Dec. 29, 1994, but pivotal data for the indication were filed in January...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth